NewsMeter
Billions in market capitalization came off Novo Nordisk after clinical trial results for CagriSema, its next-generation weight-loss drug, disappointed investors.
Shareholders have since filed suit, claiming the company misled the market about the drug's tolerability profile before those results were known.
The lawsuit frames the gap between Novo Nordisk's pre-trial disclosures and the actual trial outcome as actionable investor harm.
The tolerability allegation The core claim is that Novo Nordisk characterized CagriSema's tolerability more favorably than the clinical evidence ultimately supported.
Keep reading